Lanthanum nitrate hexahydrate | 68811-97-2

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 镧系含氧阴离子化合物
• 英文名称: Lanthanum nitrate hexahydrate
• 英文别名: lanthanum(3+);trinitrate;hexahydrate
• CAS: 68811-97-2
• 化学式: H₁₂LaN₃O₁₅
• 分子量: 433.012
• InChiKey: GJKFIJKSBFYMQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.67
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  195
• 氢给体数：
  6
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  Lanthanum nitrate hexahydrate 以 水 为溶剂， 生成 硝酸镧
  参考文献：
  名称：

  Process for preparing dialkyl carbonates

  摘要：

  提供了一种工业上有利的制备二元碳酸酯的过程。该过程的特点在于，在存在至少一种稀土氧化物作为催化活性成分的催化剂的存在下，将碳酸烷和醇进行酯交换反应。根据该过程，由于催化剂的优异活性，酯交换反应进展迅速，并且在反应结束后可以轻松分离催化剂，从而实现高效的二元碳酸酯的分离和纯化。

  公开号：

  US05430170A1
• 作为产物：
  描述：

  lanthanum(III) oxide 、 水 、 硝酸 以 水 为溶剂， 生成 Lanthanum nitrate hexahydrate
  参考文献：
  名称：

  Eriksson, Birgitta; Larsson, Lars Olof; Niinisto, Lauri, Inorganic Chemistry, 1980, vol. 19, # 5, p. 1207 - 1210

  摘要：

  DOI：

文献信息

• Organophosphorus-Modified Lanthanide Nitrates as Potential Actinide Oxide Aerosol Surrogates
  作者：Timothy J. Boyle、Xavier J. Robinson、Fernando Guerrero、Diana Perales、Joshua A. Hubbard、Roger E. Cramer

  DOI：10.1021/acs.inorgchem.0c02428

  日期：2020.12.7

  nitrate hydrates ([Ln(κ2-NO3)3·nH2O]) were dissolved in the presence of tributylphosphate (O═P(O(CH2)3CH3)3) referred to as TBP) in kerosene or triphenylphosphate (O═P(O(C6H5) referred to as TPhP) in acetone. The crystal structure of the TPhP derivatives of the lanthanide nitrate series and uranium nitrate were solved as [Ln(κ2-NO3)3(TPhP)3] (Ln = La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu)

  在搜索用于从钚铀氧化还原萃取（PUREX）处理烧伤，一系列硝酸镧系元素水合物（[LN（气雾剂铀废产物合适的模拟物的κ 2 - NO 3）3 · Ñ ħ 2 O]）溶解在存在煤油中的磷酸三丁酯（O═P（O（CH 2）3 CH 3）3）称为三丁酸酯或丙酮中的磷酸三苯酯（O═P（O（C 6 H 5）称为TPhP））的晶体结构硝酸镧系和铀硝酸的TPhP衍生物就解决了为[LN（κ 2 - NO3）3（TPhP）3 ]（LN =的La，Ce的，镨，钕，钐，铕，钆，铽，镝，何，铒，的Tm，镱，路）和[U（O）2（κ 2 - NO 3）2（TPhP）2 ]（U）。镧系元素-TBP，Ln和U使用FTIR光谱，31 P NMR光谱，热重分析和X射线荧光光谱进一步表征。此外，通过PXRD分析发现使用箱式炉模拟热解条件对镧系元素TBP，Ln和U进行热处理，以生成所有系统的磷酸盐相（LnP 3 O 9或UP 2 O
• Process for producing adamantane compound
  申请人：——

  公开号：US20030018226A1

  公开（公告）日：2003-01-23

  There is provided a process for producing adamantane and analogues thereof, namely a hydrocarbon having an adamantane structure which process comprises isomerizing a tricyclic saturated hydrocarbon having ten or more carbon atoms in the presence of a catalyst in which one or two or more metals selected from among the metals belonging to group VIII in the Periodic Table (group 8 to 10 in the new Periodic Table) are supported on zeolite by means of an ion exchange method. It is made possible by the above process to efficiently produce adamantane and analogues thereof in the presence of a solid catalyst without the use of hydrogen chloride.

  提供了一种生产金刚烷及其类似物的过程，即在催化剂的存在下异构化具有十个或更多碳原子的三环饱和碳氢化合物，该催化剂中的一种或两种或更多金属被选择从周期表中属于第VIII组金属（新周期表中的第8到10组）的金属通过离子交换方法支持在沸石上。通过上述过程，可以在无需使用氯化氢的情况下，在固体催化剂的存在下高效地生产金刚烷及其类似物。
• 2-oxoquinoline compounds and pharmaceutical uses thereof
  申请人：——

  公开号：US20030191069A1

  公开（公告）日：2003-10-09

  A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: 1 (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.

  一种2-氧基喹啉化合物或其药学上可接受的盐，其通式为[I]:1（其中公式中的每个符号如说明中所确定的那样），以及其医药用途。本发明的化合物[I]及其药学上可接受的盐，能够选择性地作用于大麻素受体，特别是外周型大麻素受体，并且对中枢神经系统的副作用较少，具有很强的免疫抑制作用、抗炎作用或抗过敏作用。因此，这些化合物可用作大麻素受体（特别是外周型大麻素受体）调节剂、免疫抑制剂、抗炎剂和抗过敏剂。
• Therapeutic diphenyl ether ligands
  申请人：Fliri J. Anton

  公开号：US20060058361A1

  公开（公告）日：2006-03-16

  This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.

  本发明涉及式Ia、Ib或Ic化合物及其制药组合物：或其前药和药学上可接受的载体，其中R基在规范中定义；在其中，虚线表示可选的双键。本发明还涉及治疗、诊断和预防与5HT受体相关的中枢神经系统疾病的方法，包括肥胖症、注意力缺陷障碍、偏头痛、抑郁症、癫痫、焦虑症、阿尔茨海默病、戒毒引起的戒断症状、疼痛、精神分裂症、与压力相关的障碍、惊恐障碍、睡眠障碍、恐惧症、强迫症、创伤后应激障碍、免疫系统抑制、压力诱导的胃肠功能障碍、压力诱导的心血管功能障碍和性功能障碍。
• 2-oxoquinoline compounds and medicinal uses thereof
  申请人：Japan Tobacco Inc.

  公开号：US06509352B1

  公开（公告）日：2003-01-21

  A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]:   (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.

  一种2-氧基喹啉化合物或其药学上可接受的盐，其通用式为[I]（其中公式中的每个符号如说明所确定），以及其药用。本发明的化合物[I]及其药学上可接受的盐选择性作用于大麻素受体，特别是作用于外周型大麻素受体，并且对中枢神经系统的副作用较少，具有很强的免疫抑制作用、抗炎作用或抗过敏作用。因此，这些化合物可用作大麻素受体（特别是外周型大麻素受体）调节剂、免疫抑制剂、抗炎药和抗过敏药。

表征谱图